| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
PI3Kα 3.5 nM (IC50) PI3Kδ 4.6 nM (IC50) mTOR 21.3 nM (IC50)
PI3K/mTOR Inhibitor-11 targets PI3Kalpha, PI3Kdelta, and mTOR with IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM, respectively. This dual inhibition profile allows it to block both upstream and downstream nodes of the PI3K/AKT/mTOR pathway. |
|---|---|
| ln Vitro |
PI3K/mTOR Inhibitor-11 (compound 8o) has been shown to decrease the viability of several human cancer cell lines, including HT29, HCT15, H3122, HeLa, SW620, and H446. Its IC50 values are 0.25, 0.17, 0.29, 0.09, 0.16, and 0.97 μM, respectively[1]. HeLa and SW620 cell colony formation rates are reduced by PI3K/mTOR Inhibitor-11 (0-1.25 μM, 15 days)[1]. HeLa and SW620 cells are arrested at the G0/G1 phases by PI3K/mTOR Inhibitor-11 (0-2.5 μM, 24 h)[1]. In HeLa cells, phosphorylated AKT and S6 proteins are suppressed by PI3K/mTOR Inhibitor-11 (0-2.5 μM, 24 h)[1].
PI3K/mTOR Inhibitor-11 (compound 8o) reduces the viability of multiple human cancer cell lines, with IC50 values of 0.25 microM (HT29), 0.17 microM (HCT15), 0.29 microM (H3122), 0.09 microM (HeLa), 0.16 microM (SW620), and 0.97 microM (H446). It also reduces colony formation and induces G0/G1 cell cycle arrest in HeLa and SW620 cells. |
| ln Vivo |
Compound 8o, administered intragastrically at doses of 15–60 mg/kg, inhibits the growth of HeLa and SW620 xenograft cancers[1]. Oral bioavailability (76.81%) is demonstrated with PI3K/mTOR Inhibitor-11 (1 mg/kg for iv, 10 mg/kg for po, rats)[1].
PI3K/mTOR Inhibitor-11 (compound 8o) inhibits the growth of HeLa and SW620 xenograft tumors in female BALB/c nude mice when administered intragastrically at doses of 15, 30, and 60 mg/kg daily for 30 days. Tumor growth inhibitions (TGI) of 80.22%, 73.50%, and 60.79% are observed in the HeLa xenograft model. |
| Enzyme Assay |
A typical biochemical kinase inhibition assay is performed using recombinant PI3Kalpha, PI3Kdelta, and mTOR kinases. Increasing concentrations of PI3K/mTOR Inhibitor-11 (0.1 nM to 10 uM) are incubated with the enzyme, ATP, and a substrate. After the reaction, detection reagents (e.g., ADP-Glo or HTRF reagents) are added, and luminescence or fluorescence is measured to calculate the IC50 values.
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: HeLa and SW620 cells Tested Concentrations: 0, 0.15625, 0.625, 1.25 μM Incubation Duration: 24 h Experimental Results: Affected HeLa cells' apoptosis rate from 6.10 to 66.04% in a dose-dependent manner. Western Blot Analysis[1] Cell Types: HeLa Tested Concentrations: 0 , 0.15625, 0.625, 1.25, 2.5 μM Incubation Duration: 24 h Experimental Results: Suppressed the phosphorylated AKT (Ser473 and Thr308) and S6 proteins. For cell viability assays, HeLa, SW620, HT29, and other cancer cell lines are seeded in 96-well plates. Cells are treated with a dilution series of PI3K/mTOR Inhibitor-11 (0.01-2.5 microM) for 72 hours. Cell viability is measured using the CellTiter-Glo luminescent assay. For Western blot analysis, cells are treated with the compound (0-2.5 microM) for 24 hours, and p-AKT (S473/T308) and p-S6 levels are assessed. |
| Animal Protocol |
Animal/Disease Models: HeLa and SW620 xenograft models of female BALB/c nude mice[1].
Doses: 15, 30, and 60 mg/kg Route of Administration: intragastric (po) administration, daily for 30 days. Experimental Results: The TGIs (tumor growth inhibitions): 80.22, 73.50, and 60.79% in the HeLa xenograft model at doses of 60, 30, and 15 mg/kg, respectively. TGIs: 81.03, 70.81, and 60.58% in the SW620 xenograft model at doses of 60, 30, and 15 mg/kg, respectively. Animal/Disease Models: Rats[1]. Doses: 1 mg/kg for iv, 10 mg/kg for po Route of Administration: iv, po Experimental Results: pharmacokinetic/PK parameters of PI3K/mTOR Inhibitor-11 (compound 8o) dose (mg/kg) T1/2 (h) Cmax (ng/mL) CL (mL/min/kg) F (%) 1 (iv) 17.2 10 (po) 2.6 2995 76.81% In a xenograft model, female BALB/c nude mice bearing established HeLa or SW620 tumors (∼100-200 mm3) are randomized. PI3K/mTOR Inhibitor-11 is administered daily via intragastric (oral) gavage at 15, 30, and 60 mg/kg for 30 days. Tumor volumes are measured with calipers twice weekly, and body weights are monitored for toxicity. Endpoint analysis includes tumor weight and TGI calculation. |
| ADME/Pharmacokinetics |
PI3K/mTOR Inhibitor-11 demonstrates oral bioavailability (F = 76.81%) in rats following IV (1 mg/kg) and PO (10 mg/kg) administration. The compound regulates the PI3K/AKT/mTOR pathway by inhibiting AKT and S6 protein phosphorylation.
|
| Toxicity/Toxicokinetics |
No specific toxicology data is reported beyond body weight monitoring during efficacy studies. As a PI3K/mTOR inhibitor, potential class-related toxicities include metabolic side effects and gastrointestinal disturbances.
|
| References | |
| Additional Infomation |
PI3K/mTOR Inhibitor-11 (CAS: 2845104-25-6) is an orally bioavailable dual PI3K/mTOR inhibitor (PI3Kalpha IC50 = 3.5 nM; PI3Kdelta IC50 = 4.6 nM; mTOR IC50 = 21.3 nM). It inhibits AKT and S6 phosphorylation, reduces viability of multiple cancer cell lines (HeLa, SW620, HT29, HCT15, H3122, H446), and demonstrates in vivo efficacy in HeLa and SW620 xenograft models.
|
| Molecular Formula |
C27H21N7
|
|---|---|
| Molecular Weight |
443.50
|
| Exact Mass |
443.185
|
| CAS # |
2845104-25-6
|
| PubChem CID |
168295564
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
791
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC2=CN=C3C=CC(=CC3=C2N1C4=CN=C(C=C4)C(C)(C)C#N)C5=CN=C6C(=C5)C=CN6
|
| InChi Key |
JDUUUKXVZOZLSS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H21N7/c1-16-33-23-14-30-22-6-4-17(19-10-18-8-9-29-26(18)32-12-19)11-21(22)25(23)34(16)20-5-7-24(31-13-20)27(2,3)15-28/h4-14H,1-3H3,(H,29,32)
|
| Chemical Name |
2-methyl-2-[5-[2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[4,5-c]quinolin-1-yl]pyridin-2-yl]propanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 40 mg/mL (90.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4 mg/mL (9.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 40.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2548 mL | 11.2740 mL | 22.5479 mL | |
| 5 mM | 0.4510 mL | 2.2548 mL | 4.5096 mL | |
| 10 mM | 0.2255 mL | 1.1274 mL | 2.2548 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
